Bupivacaine/Meloxicam

Tier C — Watch / trade

Heron Therapeutics

Originator

2020

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：SCNA, COX-2, COX-1

Brand：Zynrelef

Indications (approved)：Postoperative pain

Regional status

Approved

2021-05-12

Withdrawn

China

Japan

Factories producing this API11

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

11 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Bupivacaine/Meloxicam?

Approved indications include: Postoperative pain.

When does the Bupivacaine/Meloxicam patent expire?

No public expiry year is available for Bupivacaine/Meloxicam yet; this page updates once verified.

How do I get a quote for Bupivacaine/Meloxicam intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27